CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer

Cited by papers we hold 13

• Current and future immunotherapeutic approaches in pancreatic cancer treatment · 2024
  No notice
• The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma · 2023
  No notice
• Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial · 2022
  No notice
• Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma · 2021
  No notice
• Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes · 2021
  No notice
• The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment · 2021
  No notice
• Ovarian Cancer Immunotherapy and Personalized Medicine · 2021
  No notice
• Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects · 2020
  No notice
• Harnessing tumor-associated macrophages as aids for cancer immunotherapy · 2019
  No notice
• Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features · 2019
  No notice
• Immune regulation of metastasis: mechanistic insights and therapeutic opportunities · 2018
  No notice
• Immunotherapy for pancreatic cancer: Barriers and breakthroughs · 2018
  No notice
• Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.